Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury

Journal of Hepatology

Volumn 40, Issue 3, 2004, Pages 454-463

  Tapner, Michael J ^a   Jones, Brett E ^a   Wu, Wan M ^a   Farrell, Geoffrey C ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

6 Mercaptopurine; Azathioprine; Hepatotoxicity; Mitochondrial injury; Xanthine oxidase

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALLOPURINOL; ALPHA TOCOPHEROL DERIVATIVE; AZATHIOPRINE; GLUCOSE; GLUTATHIONE; GLUTATHIONE DISULFIDE; LACTATE DEHYDROGENASE; MATRIGEL; MERCAPTOPURINE; PROTECTIVE AGENT; TROLOX C; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR;

ANIMAL CELL; ARTICLE; CELL DAMAGE; CELL DEATH; CELL PROTECTION; CELL ULTRASTRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; LIVER CELL; LIVER CELL CULTURE; LIVER INJURY; MALE; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REDUCTION;

EID: 1242292349     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2003.11.024     Document Type: Article

References (53)

1. King P., Perry M. Hepatotoxicity of chemotherapeutic and oncologic agents. Drug induced liver disease. Gastroenterol Clin North Am. 24:1995;969-990.
2. Farrell G.C. Liver disease due to drugs, anesthetics, and toxins. Sleisenger and Fordtran's gastrointestinal and liver disease. 7th ed :2002;Harcourt Health Sciences, Baltimore, MD. Chapter 73.
3. Degott C., Rueff B., Kreis H., Duboust A., Potet F., Benhamou J.P. Peliosis hepatis in recipients of renal transplants. Gut. 19:1978;748-753.
4. Read A.E., Wiesner R.H., LaBrecque D.R., Tifft J.G., Mullen K.C., Sheer R.L., et al. Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med. 104:1986;651-655.
5. Sterneck M., Wiesner R., Ascher N., Roberts J., Ferrell L., Ludwig J., Lake J. Azathioprine hepatotoxicity after liver transplantation. Hepatology. 14:1991;806-810.
6. Gane E., Portmann B., Saxena R., Wong P., Ramage J., Williams R. Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology. 20:1994;88-94.
7. Russmann S., Zimmermann A., Krahenbuhl S., Kern B., Reichen J. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol. 13:2001;287-290.
8. DeLeve L.D., Wang X., Kuhlenkamp J.F., Kaplowitz N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology. 23:1996;589-599.
9. Lee A.U., Farrell G.C. Comparative toxicity of azathioprine to rat hepatocytes and sinusoidal endothelial cells in culture. Wisse E., Knook D.L., de Zanger R., Fraser R. Cells of the hepatic sinusoid. vol. 7:1999;108-109 Kupffer Cell Foundation, Leiden.
10. Lee A.U., Farrell G.C. Mechanism of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury. J Hepatol. 35:2001;756-764.
11. Dubinsky M.C., Yang H., Hassard P.V., Seidman E.G., Kam L.Y., Abreu M.T., et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 122:2002;904-915.
12. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 43:1992;329-339.
13. Lennard L., Welch J.C., Lilleyman J.S. Thiopurine drugs in the treatment of childhood leukaemia: the importance of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br J Clin Pharmacol. 44:1997;455-461.
14. Snow J.L., Gibson L.E. The role of genetic variation in the thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol. 131:1995;193-197.
15. Chocair P.R., Duley J.A., Cameron J.S., Arap S., Ianhez L., Sabbaga E., Simmonds H.A. Does low-dose allopurinol, with azathioprine, cyclosporin and prednisolone improve renal transplant immunosuppression? Adv Exp Med Biol. 370:1994;205-208.
16. Tapner M., Liddle C., Goodwin B., George J., Farrell G.C. Interferon gamma down-regulates cytochrome P450 3A genes in primary cultures of well-differentiated rat hepatocytes. Hepatology. 24:1996;367-373.
17. Bissell D.M., Guzelian P.S. Phenotypic stability of adult rat hepatocytes in primary monolayer culture. Ann N Y Acad Sci. 349:1980;85-98.
18. Samarasinghe D.A., Farrell G.C. The central role of sinusoidal endothelial cells in hepatic hypoxia-reoxygenation injury in the rat. Hepatology. 24:1996;1230-1237.
19. Hissin P.J., Hilf R. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem. 74:1976;214-226.
20. Samarasinghe D.A., Tapner M., Farrell G.C. Role of oxidative stress in hypoxia-reoxygenation injury to cultured rat hepatic sinusoidal endothelial cells. Hepatology. 31:2000;160-165.
21. 2-dependent types of rat liver xanthine dehydrogenase shown by active site probe study. J Biol Chem. 264:1989;15930-15935.
22. Jensen M.H., Jørgensen S. Hypoxanthine and xanthine. Bergmeyer H.O. Methods of Enzymatic Analysis. vol. 7:1985;125-133 Wiley, Chichester.
23. Qiao L., Farrell G.C. The effects of cell density, attachment subtratum and dexamethasone on spontaneous apoptosis of rat hepatocytes in primary culture. In Vitro Cell Dev Biol Anim. 35:1999;417-424.
24. Van Cruchten S., Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol. 31:2002;214-223.
25. Elion G.B. The purine path to chemotherapy. Science. 244:1989;41-47.
26. Rowland K., Lennard L., Lilleyman J.S. In vitro metabolism of 6-mercaptopurine by human liver cytosol. Xenobiotica. 29:1999;615-628.
27. Tterlikkis L., Day J.L., Brown D.A., Schroeder E.C. Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine in rabbits. Cancer Res. 43:1983;1675-1679.
28. Klein A.S., Joh J.W., Rangan U., Wang D., Bulkley G.B. Allopurinol: discrimination of antioxidant from enzyme inhibitory activities. Free Radic Biol Med. 21:1996;713-717.
29. Ali S., Diwakar G., Pawa S., Siddiqui M.R., Abdin M.Z., Ahmad F.J., Jain S.K. Xanthine oxidase-derived reactive oxygen metabolites contribute to liver necrosis: protection by 4-hydroxypyrazolo[3,4-d]pyrimidine. Biochim Biophys Acta. 1536:2001;21-30.
30. Desco M.C., Asensi M., Marquez R., Martinez-Valls J., Vento M., Pallardo F.V., et al. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes. 51:2002;1118-1124.
31. Sugihara K., Kitamura S., Yamada T., Ohta S., Yamashita K., Yasuda M., Fujii-Kuriyama Y. Aryl hydrocarbon receptor (AhR)-mediated induction of xanthine oxidase/xanthine dehydrogenase activity by 2,3,7,8-tetrachlorodibenzo- p-dioxin. Biochem Biophys Res Commun. 281:2001;1093-1099.
32. Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis. 22:2002;137-144.
33. Krähenbühl S. Mitochondria: important target for drug toxicity? J Hepatol. 34:2001;334-336.
34. White A.J. Mitochondrial toxicity and HIV therapy. Sex Transm Infect. 77:2001;158-173.
35. Berson A., De Beco V., Letteron P., Robin M.A., Moreau C., El Kahwaji J., et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology. 114:1998;764-774.
36. Kleiner D.E., Gaffey M.J., Sallie R., Tsokos M., Nichols L., McKenzie R., et al. Histopathologic changes associated with fialuridine hepatotoxicity. Mod Pathol. 10:1997;192-199.
37. Pessayre D., Mansouri A., Haouzi D., Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol. 15:1999;367-373.
38. Chitturi S., Farrell G.C. Drug induced liver disease. Schiff E., Maddrey W. Schiff's diseases of the liver. 9th ed. 2002;Lippincott Williams and Wilkins, New York. Chapter 38.
39. Mansouri A., Demeilliers C., Amsellem S., Pessayre D., Fromenty B. Acute ethanol administration oxidatively damages and depletes mitochondrial DNA in mouse liver, brain, heart, and skeletal muscles: protective effects of antioxidants. J Pharmacol Exp Ther. 298:2001;737-743.
40. Colell A., Garcia-Ruiz C., Miranda M., Ardite E., Mari M., Morales A., et al. Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Gastroenterology. 115:1998;1541-1551.
41. Colell A., Coll O., Garcia-Ruiz C., Paris R., Tiribelli C., Kaplowitz N., Fernandez-Checa J.C. Tauroursodeoxycholic acid protects hepatocytes from ethanol-fed rats against tumor necrosis factor-induced cell death by replenishing mitochondrial glutathione. Hepatology. 34:2001;964-971.
42. Nagai H., Matsumaru K., Feng G., Kaplowitz N. Reduced glutathione depletion causes necrosis and sensitization to tumor necrosis factor-alpha-induced apoptosis in cultured mouse hepatocytes. Hepatology. 36:2002;55-64.
43. Karbowski M., Kurono C., Nishizawa Y., Horie Y., Soji T., Wakabayashi T. Induction of megamitochondria by some chemicals inducing oxidative stress in primary cultured hepatocytes. Biochim Biophys Acta. 1349:1997;242-250.
44. Leist M., Single B., Castoldi A.F., Kühnle S., Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med. 185:1997;1481-1486.
45. Richter C., Schweizer M., Cossarizza A., Franceschi C. Control of apoptosis by the cellular ATP level. Fed Eur Biochem Soc Lett. 378:1996;107-110.
46. Kroemer G., Dallaporta B., Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol. 60:1998;619-642.
47. Maia L., Mira L. Xanthine oxidase and aldehyde oxidase: a simple procedure for the simultaneous purification of rat liver. Arch Biochem Biophys. 400:2002;48-53.
48. Peralta C., Xaus C., Bartrons R., Leon O.S., Gelpi E., Rosello-Catafau J. Effect of ozone treatment on reactive oxygen species and adenosine production during hepatic ischemia-reperfusion. Free Radic Res. 33:2000;595-605.
49. Jeon B.R., Yeom D.H., Lee S.M. Protective effect of allopurinol on hepatic energy metabolism in ischemic and reperfused rat liver. Shock. 15:2001;112-117.
50. Fernandez-Checa J.C., Kaplowitz N., Garcia-Ruiz C., Colell A., Miranda M., Mari M., et al. GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Am J Physiol. 273:1997;G7-G17.
51. Innocenti F., Danesi R., Bocci G., Fogli S., Di Paolo A., Del Tacca M. Metabolism of 6-mercaptopurine in the erythrocytes, liver, and during kidney of rats during multiple-dose regimens. Cancer Chemother Pharmacol. 43:1999;133-140.
52. Stirpe F., Ravaioli M., Battelli M.G., Musiani S., Grazi G.L. Xanthine oxidoreductase activity in human liver disease. Am J Gastroenterol. 97:2002;2079-2085.
53. Guerciolini R., Szumlanski C., Weinshilboum R.M. Human liver xanthin oxidase: nature and extent of individual variation. Clin Pharmacol Ther. 50:1991;663-672.